Intratympanic Gentamicin
Treatment for Meniere's Disease
Typical Dosage: 20-40 mg/mL, 0.3-0.5 mL per injection
Effectiveness
83%
Safety Score
55%
Clinical Trials
2
Participants
4.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
20-40 mg/mL, 0.3-0.5 mL per injection
Time to Effect
Days to weeks
Treatment Duration
1-4 injections per series
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$600
Side Effect Mgmt:$300
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
0.55
Outcome-Based Costs
Cost per Responder
$2,941
Cost per Remission
$3,571
Comparison vs Intratympanic Dexamethasone
Cost Difference
+$500/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Intratympanic Gentamicin Outcomes
for Meniere's Disease
Efficacy Outcomes
Overall Effectiveness
+83%
Response Rate
+88%
Remission Rate
+70%
Common Side Effects
Permanent hearing loss
+20%
Transient vertigo
+15%
Ear discomfort
+8%
Tinnitus
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov